

Special Issue

Skin Cancer: Recent Advances in Diagnosis, Treatment, and Prevention

Message from the Guest Editor

Skin cancer is by far the most common malignancy worldwide, affecting men and women of every skin color. The incidence of both melanoma and non-melanoma skin cancer (keratinocyte skin cancer such as basal cell carcinoma and squamous cell carcinoma) has increased in recent decades. According to the World Health Organisation (WHO), between 2 and 3 million non-melanoma skin cancers and approximately 132,000 melanoma skin cancers are diagnosed globally each year. One in every three cancers diagnosed annually is a skin cancer.

Tremendous progress has been achieved in recent years in the understanding of the molecular pathogenesis of skin cancer, leading to the development of new therapeutic strategies. In the last decade, there has been a paradigm shift in how we approach the treatment of skin cancer, especially advanced melanoma, due to the unprecedented success of MAPK pathway and immune checkpoint inhibitors. The latter have revolutionized the treatment landscape of many hematological and solid tumors.

Guest Editor

Prof. Dr. Alexander Kreuter

1. Department of Dermatology, Venereology and Allergology, Helios St. Elisabeth Hospital Oberhausen, University Witten/Herdecke, 46045 Oberhausen, Germany
2. Department of Dermatology, Venereology and Allergology, Helios St. Johannes Hospital Duisburg, 47166 Duisburg, Germany

Deadline for manuscript submissions

closed (31 December 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/170834

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)